Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Net Income towards Common Stockholders (2016 - 2024)

Historic Net Income towards Common Stockholders for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.

  • Summit Therapeutics' Net Income towards Common Stockholders fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$65.6 million, marking a year-over-year increase of 3237.67%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
  • Latest data reveals that Summit Therapeutics reported Net Income towards Common Stockholders of -$65.6 million as of Q4 2024, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
  • Over the past 5 years, Summit Therapeutics' Net Income towards Common Stockholders peaked at -$9.0 million during Q1 2020, and registered a low of -$65.6 million during Q4 2024.
  • Moreover, its 4-year median value for Net Income towards Common Stockholders was -$20.5 million (2023), whereas its average is -$32.8 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 22950.72% in 2020, then plummeted by 2096.81% in 2023.
  • Quarter analysis of 4 years shows Summit Therapeutics' Net Income towards Common Stockholders stood at -$9.0 million in 2020, then plummeted by 125.55% to -$20.3 million in 2022, then crashed by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
  • Its last three reported values are -$65.6 million in Q4 2024, -$60.8 million for Q3 2024, and -$36.2 million during Q4 2023.